Hutchmed (China) Limited American Depositary Shares (HCM)
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopathy (HCM).
US pharma restrictions won't affect Hutchmed operations, says CEO
Weiguo Su, CEO of Chinese pharma company HUTCHMED, talks about the company's latest earnings report, and why it's positioned to be 'sustainably profitable' from this point despite some external challenges.
HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM ) Q4 2024 Earnings Conference Call March 19, 2025 8:00 AM ET Company Participants David Ng - Head:IR Wei-Guo Su - CEO & Chief Scientific Officer Johnny Cheng - CFO George Yuan - Head of Commercial Michael Shi - EVP, Head of R&D & Chief Medical Officer Conference Call Participants Clara Dong - Jefferies Alec Stranahan - Bank of America Julie Simmonds - Panmure Liberum Adam McCarter - Cavendish Chen Chen - UBS Cindy Chai - HSBC David Ng Welcome, everyone. Thank you for joining HUTCHMED 2024 Full Year Results Call.
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) reported 2024 earnings of 22 cents per ADS or 4 cents per share, down 59 cents or 12 cents a year ago. Sales fell 25% year over year to $630.20 million.
HUTCHMED (HCM) Upgraded to Buy: Here's Why
HUTCHMED (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 72.8% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
On Wednesday, Hutchmed (China) Limited HCM entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million (RMB 4.478 billion) in cash to GP Health Service Capital Co., Ltd and Shanghai Pharmaceuticals Holding Co., Ltd.
Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales
Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the billionaire and his flagship conglomerate look to ramp up capital and pivot towards core operations at the drugmaker.
Paycor HCM: Positive On The Mid-Term Growth Outlook (Rating Upgrade)
I am upgrading PYCR to a buy rating due to optimistic mid-term guidance and strong earnings growth potential. PYCR's new guidance indicates sustainable mid-teens recurring revenue growth and >800 bps adj EBIT margin expansion, driving >20% adj EBIT growth. Successful upmarket traction, increased sales headcount, and strong broker relationships are key drivers of PYCR's positive outlook.
HUTCHMED (China) Ltd (HCM) Shares Up 2.9% on Oct 2
Shares of HUTCHMED (China) Ltd (HCM, Financial) surged 2.90% in mid-day trading on Oct 2. The stock reached an intraday high of $21.10, before settling at $20.58, up from its previous close of $20.00.
Top Wall Street Forecasters Revamp Paycor HCM Price Expectations Ahead Of Q4 Earnings
Paycor HCM, Inc. PYCR is expected to release earnings results for its fourth quarter, after the closing bell on Wednesday, Aug. 14.
Hutchmed Growing Sales By 64% In H1 2024
Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of oncology products from the approval of FRUZAQLA in the E.U. and Japan.
